# A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

> **NCT05262959** · PHASE2 · COMPLETED · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 30 (actual)

## Conditions studied

- Donafenib

## Interventions

- **DRUG:** Donafenib, PD-1
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT05262959
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262959, "A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05262959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*